natgillin/translations-raw huggingface dataset:
In small short-term clinical trials, approximately 12.5% of paediatric patients were observed to experience adverse reactions, the majority of which were local, non-serious ocular reactions such as conjunctival hyperaemia, eye irritation, eye discharge, and lacrimation increased (see also section 5.1). 
U manjim kratkoročnim kliničkim ispitivanja nuspojave su zabilježene kod otprilike 12,5% pedijatrijskih bolesnika, od kojih su većina bile lokalne, neozbiljne okularne reakcije poput konjunktivalne hiperemije, iritacije oka, iscjetka iz oka i pojačanog suzenja (vidjeti također dio 5.1).
To prevent contamination of the dropper tip and suspension, care must be taken not to touch the eyelids, surrounding areas or other surfaces with the dropper tip of the bottle. 
Da bi se spriječila kontaminacija vrha kapaljke i suspenzije, potrebno je paziti da se vrhom kapaljke ne dotiču vjeđe, okolna područja ili druge površine.
AZOPT contains brinzolamide which belongs to a group of medicines called carbonic anhydrase inhibitors. 
AZOPT sadrži brinzolamid koji pripada skupini lijekova koja se naziva inhibitori karboanhidraze.
The use of AZOPT is not recommended during pregnancy or breast-feeding. 
Primjena AZOPTA ne preporučuje se tijekom trudnoće ili dojenja.
In subjects with the highest degree of renal impairment inhibition of total CA activity was greater although it was inferior to 90% at steady-state. 
Kod ispitanika s najvećim stupnjem oštećenja bubrega inhibicija ukupne aktivnosti CA je bila veća, iako manja od 90% u stanju dinamičke ravnoteže.
In clinical studies involving 2732 patients treated with AZOPT as monotherapy or adjunctive therapy to timolol maleate 5 mg/ml, the most frequently reported treatment-related adverse reactions were: dysgeusia (6.0%) (bitter or unusual taste, see description below) and temporary blurred vision (5.4%) upon instillation, lasting from a few seconds to a few minutes (see also section 4.7). 
U kliničkim studijama koje su uključile 2732 bolesnika liječenih AZOPTOM, kao monoterapija ili dodatna terapija s timolol maleatom 5 mg/ml najčešće zabilježene nuspojave povezane s terapijom bile su: disgeuzija (6,0%) (gorak ili neobičan okus, vidjeti opis niže) i privremeno zamagljen vid (5,4%) nakon ukapavanja, u trajanju od nekoliko sekundi do nekoliko minuta (vidjeti također dio 4.7).
In plasma, both brinzolamide and Ndesethylbrinzolamide concentrations are low and generally below assay quantitation limits (<7.5 ng/ml). 
U plazmi su koncentracije i brinzolamida i N-desetilbrinzolamida niske i općenito su ispod limita testa za određivanje (<7,5 ng/ml).
Benzalkonium chloride, which is commonly used as a preservative in ophthalmic products, has been reported to cause punctate keratopathy and/or toxic ulcerative keratopathy. 
Benzalkonijev klorid, koji se uobičajeno primjenjuje kao konzervans u oftalmološkim preparatima, može uzrokovati točkastu keratopatiju i/ili toksičnu ulcerativnu keratopatiju.
The result is a reduction in intraocular pressure (IOP) which is a major risk factor in the pathogenesis of optic nerve damage and glaucomatous visual field loss. 
Rezultat je redukcija intraokularnog tlaka (IOT) koji je glavni faktor rizika u patogenezi oštećenja očnog živca i gubitka vidnog polja kod glaukoma.
Rare: memory impairment, somnolence Not Known: tremor, hypoaesthesia, ageusia 
Rijetko: zaboravljivost, somnolencija Nepoznato: tremor, hipoestezija, ageuzija
The cytochrome P-450 isozymes responsible for metabolism of brinzolamide include CYP3A4 (main), CYP2A6, CYP2C8 and CYP2C9. 
Izoenzimi citrokroma P-450, koji su odgovorni za metabolizam brinzolamida su CYP3A4 (glavni), CYP2A6, CYP2C8 i CYP2C9.
Patients with significant renal tubular immaturity or abnormalities should only receive brinzolamide after careful consideration of the risk benefit balance because of the possible risk of metabolic acidosis. 
Bolesnici s nerazvijenim ili abnormalnim renalnim tubulima smiju primiti brinzolamid tek nakon pažljive procjene rizika i koristi zbog mogućeg rizika od metaboličke acidoze.
This may reduce the systemic absorption of medicinal products administered via the ocular route and result in a decrease in systemic side effects. 
Na taj se način može smanjiti sistemska apsorpcija lijekova primijenjenih u oko, što rezultira smanjenjem sistemskih nuspojava.
The inhibition of total RBC CA activity at steady state was approximately 70-75%. 
Inhibicija ukupne CA aktivnosti u eritrocitima u stanju dinamičke ravnoteže bila je oko 70-75%.
• Use up one bottle before opening the next bottle. 
• Prije nego otvorite novu bočicu, do kraja iskoristite prvu.
Following a 4 week run-in with travoprost, patients with an IOP ≥19 mmHg were randomized to receive added treatment with brinzolamide or timolol. 
Nakon uključivanja i 4 tjedna terapije travoprostom; bolesnici s IOT ≥19 mmHg su randomizirani na primanje dodatne terapije brinzolamida ili timolola.
Specifically, patients wearing contact lenses have not been studied and careful monitoring of these patients when using brinzolamide is recommended, since carbonic anhydrase inhibitors may affect corneal hydration and wearing contact lenses might increase the risk for the cornea. 
Posebno, u ispitivanjima nisu sudjelovali bolesnici koji nose kontaktne leće, stoga se preporučuje pažljivo praćenje tih bolesnika kod primjene brinzolamida, jer inhibitori karboanhidraze mogu utjecati na vlažnost rožnice i nošenje kontaktnih leća kod njihove primjene može povećati rizik za rožnicu.
Eye ointments should be administered last. 
Masti za oko se moraju primijeniti posljednje.
Patients must be instructed to remove contact lenses prior to the application of AZOPT and wait at least 15 minutes after instillation of the dose before reinsertion. 
Bolesnike se mora upozoriti da izvade kontaktne leće prije primjene AZOPTA i da pričekaju najmanje 15 minuta nakon ukapavanja prije ponovnog stavljanja leća.
A clinical trial was conducted with AZOPT in 32 paediatric patients less than 6 years of age, diagnosed with glaucoma or ocular hypertension. 
Kliničko ispitivanje primjene AZOPTA provedeno je u 32 pedijatrijska bolesnika mlađa od 6 godina s dijagnosticiranim glaukomom ili očnom hipertenzijom.
Instruct the patient to shake the bottle well before use. 
Preporučite bolesniku da dobro protrese bočicu prije primjene.
Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humour secretion, presumably by slowing the formation of bicarbonate ions with subsequent reduction in sodium and fluid transport. 
Inhibicijom karboanhidraze u cilijarnim nastavcima u oku smanjuje se sekrecija očne vodice, vjerojatno usporavanjem stvaranja bikarbonatnih iona s posljedičnom redukcijom transporta natrija i tekućine.
Developmental toxicity studies in rabbits with oral doses of brinzolamide of up to 6 mg/kg/day (125 times the recommended human ophthalmic dose) revealed no effect on foetal development despite significant maternal toxicity. 
Ispitivanja razvojne toksičnosti kod kunića s peroralnim dozama brinzolamida do 6 mg/kg/dan (125 puta više od preporučene doze u oko za ljude) nisu pokazale nikakav utjecaj lijeka na razvoj ploda unatoč znatnoj toksičnosti za majku.
Due to its high affinity for CA-II, brinzolamide distributes extensively into the red blood cells (RBCs) and exhibits a long half-life in whole blood (mean of approximately 24 weeks). 
Zahvaljujući svom visokom afinitetu za CA-II, brinzolamid se distribuira najvećim dijelom u eritrocite i ima dugi poluvijek eliminacije u punoj krvi (srednja vrijednost od oko 24 tjedna).
Caution is advised if CYP3A4 inhibitors are given concomitantly. 
Kod istodobne primjene CYP3A4 inhibitora preporučuje se oprez.
AZOPT is not recommended during pregnancy and in women of childbearing potential not using contraception. 
Ne preporučuje se koristiti AZOPT tijekom trudnoće niti u žena reproduktivne dobi koje ne koriste kontracepciju.
There was an overall higher incidence of non-serious ocular adverse reactions, mainly related to signs of local irritation, in the brinzolamide/travoprost groups. 
U cjelini je zabilježena veća incidencija neozbiljnih nuspojava na oku, većinom znakovi lokalne iritacije, u grupi na terapiji brinzolamidom/travoprostom.
Use this much unless your doctor told you to do something different. 
Pridržavajte se ovih uputa osim ako Vaš liječnik nije odredio drugačije.
Pull down your eyelid with a clean finger, until there is a ‘pocket' between the eyelid and your eye. 
Donju vjeđu lagano povucite prema dolje s čistim prstom, tako da nastane spojnični džep između očne jabučice i donje vjeđe.
AZOPT has not been studied in patients wearing contact lenses. 
AZOPT nije ispitivan kod bolesnika koji nose kontaktne leće.
Brinzolamide and N-desethylbrinzolamide are the predominant components in the urine along with trace levels (<1%) of the N-desmethoxypropyl and O-desmethyl metabolites. 
Brinzolamid i N-desetil-brinzolamid su predominantne sastavnice u urinu, zajedno s Ndezmetoksipropilnim i O-dezmetilnim metabolitima u tragovima (<1%).
Manufacturer S.A. Alcon - Couvreur N.V. Rijksweg 14 
S.A. Alcon-Couvreur N.V. Rijksweg 14
- if you are taking other sulphonamide medicines - if you have a specific form of glaucoma in which the pressure inside the eye rises due to deposits that block fluid draining out (pseudoexfoliative glaucoma or pigmentary glaucoma) or a specific form of glaucoma in which the pressure inside the eye (sometimes rapidly) rises because the eye bulges forward and blocks fluid draining out (narrow-angle glaucoma) 
ako imate specifičan oblik glaukoma pri kojem tlak unutar oka raste zbog naslaga koje sprječavaju odvođenje očne vodice iz oka (pseudoeksfolijativni glaukom ili pigmentni glaukom) ili specifičan oblik glaukoma pri kojem tlak unutar oka raste (ponekad brzo) zbog izbočenja očne jabučice koje sprječava odvođenje očne vodice iz oka (glaukom zatvorenog kuta)
• Do not touch your eye or eyelid, surrounding areas or other surfaces with the dropper. 
• Izbjegavajte dodir kapaljke s okom ili vjeđom, okolnim područjima ili drugim površinama.
AZOPT 10 mg/ml eye drops, suspension 
AZOPT 10 mg/ml kapi za oko, suspenzija
What AZOPT looks like and contents of the pack AZOPT is a milky liquid (a suspension) supplied in a pack containing a 5 ml or a 10 ml plastic (droptainer) bottle with a screw cap, or in a pack containing three 5 ml plastic (droptainer) bottles with screw caps. 
AZOPT je mliječno bijela tekućina (suspenzija), dostupna u pakiranju koje sadrži plastičnu bočicu (droptainer) od 5 ml ili 10 ml s navojnim zatvaračem, ili u pakiranju koje sadrži tri plastične bočice (droptainer) od 5 ml s navojnim zatvaračem.
At steady-state, brinzolamide and its metabolite RBC concentrations ranged from 22.0 to 46.1 and 17.1 to 88.6 µM, respectively. 
U stanju dinamičke ravnoteže koncentracije brinzolamida i njegovog metabolita u eritrocitima bile su od 22,0 do 46,1 M, odnosno 17,1 do 88,6 M.
When substituting another ophthalmic antiglaucoma agent with AZOPT, discontinue the other agent and start the following day with AZOPT. 
Kada drugi oftalmološki lijek za liječenje glaukoma zamjenjujete AZOPTOM, prekinite terapiju drugim lijekom, a zatim sljedećeg dana započnite terapiju AZOPTOM.
Temporary blurred vision or other visual disturbances may affect the ability to drive or use machines (see also section 4.8). 
Prolazno zamućenje vida ili drugi smetnje vida mogu imati utjecaj na upravljanje vozilima ili strojevima (vidjeti također dio 4.8).
Gastrointestinal, nervous system, haematological, renal and metabolic effects are generally associated with systemic carbonic anhydrase inhibitors. 
Gastrointestinalni, hematološki i metabolički učinci te učinci na živčani sustav i bubrege općenito su povezani sa sistemskim inhibitorima karboanhidraze.
AZOPT may impair the ability to perform tasks requiring mental alertness and/or physical coordination. 
AZOPT može umanjiti sposobnost obavljanja zadaća koje zahtijevaju pribranost i/ili tjelesnu koordinaciju.
The adverse reactions seen with the adjunctive therapy have been observed with each active substance alone. 
Primijećene nuspojave zabilježene kod dodatne terapije opažene su sa svakom djelatnom tvari zasebno.
If you forget to use AZOPT 
Ako ste zaboravili primijeniti AZOPT
The concomitant administration of AZOPT and oral carbonic anhydrase inhibitors has not been studied and is not recommended (see also section 4.5). 
Istodobna primjena AZOPTA i oralnih inhibitora karboanhidraze nije ispitivana te se stoga ne preporučuje (vidjeti također dio 4.5).
AZOPT 10 mg/ml eye drops, suspension brinzolamide 
AZOPT 10 mg/ml kapi za oko, suspenzija brinzolamid
Following topical ocular administration, brinzolamide is absorbed into the systemic circulation. 
Nakon lokalne primjene u oko, brinzolamid se apsorbira u sistemsku cirkulaciju.
Among patients who were naive to IOP therapy (10 patients), the efficacy of AZOPT was similar to that seen previously in adults, with mean IOP reductions from baseline ranging up to 5 mmHg. 
Među bolesnicima koji do tada nisu liječeni IOT terapijom (10 bolesnika), djelotvornost AZOPTA bila je slična ranije zabilježenoj kod odraslih, sa srednjim vrijednostima smanjenja IOT-a od početne vrijednosti do 5 mmHg.
Dose-related decreases in foetal weights were observed in pups of dams receiving brinzolamide orally ranging from a slight decrease (about 5-6%) at 2 mg/kg/day to nearly 14% at 18 mg/kg/day. 
O doziranju ovisno smanjenje težine ploda zabilježeno je kod mladunaca ženki koje su brinzolamid primale peroralno, u rasponu od manjeg smanjenja (približno 5 do 6%) pri 2 mg/kg/dan do skoro 14% smanjenja pri 18 mg/kg/dan.
Opened (1): Opened (2): Opened (3): 
Otvoreno (1): Otvoreno (2): Otvoreno (3):
N-Desethylbrinzolamide accumulated in RBCs to steady state within 2028 weeks reaching concentrations ranging from 6-30 µM. 
N-desetil-brinzolamid se akumulirao u eritrocitima do stanja dinamičke ravnoteže unutar 20-28 tjedana dosežući koncentracije u rasponu od 6-30 M.
The safety and efficacy of AZOPT in infants, children and adolescents aged 0 to 17 years have not been established and its use is not recommended in infants, children or adolescents 
Sigurnost i djelotvornost AZOPTA u dojenčadi, djece i adolescenata u dobi od 0 do 17 godina nisu ustanovljene, te se njegova primjena u dojenčadi, djece i adolescenata ne preporučuje.
Subjects with moderate renal impairment (creatinine clearance of 30-60 ml/minute) were administered 1 mg of brinzolamide twice daily orally for up to 54 weeks. 
Ispitanici s umjerenim oštećenjem bubrega (klirens kreatinina od 30-60 ml/min) dobivali su dvaput dnevno peroralno brinzolamid od 1 mg u razdoblju do 54 tjedna.
Since AZOPT contains benzalkonium chloride, close monitoring is required with frequent or prolonged use in dry eye patients, or in conditions where the cornea is compromised. 
Budući da AZOPT sadrži benzalkonijev klorid, kod česte ili dugotrajne primjene tog lijeka potrebno je pomno praćenje bolesnika sa suhim okom ili u uvjetima kada je oštećena rožnica.
The following pack sizes are available: outer cartons containing 1 x 5 ml, 3 x 5 ml and 1 x 10 ml bottles. 
Dostupne su sljedeće veličine pakiranja: kutije s 1 x 5 ml, 3 x 5 ml i 1 x 10 ml bočicama.
In clinical studies, AZOPT was used concomitantly with prostaglandin analogues and timolol ophthalmic preparations without evidence of adverse interactions. 
U kliničkim studijama u kojima je AZOPT primjenjivan istodobno s analozima prostaglandina i oftalmološkim pripravcima timolola, nisu zabilježene neželjene interakcije.
Brinzolamide saturation of RBC CA-II was achieved within 4 weeks (RBC concentrations of approximately 20 µM). 
Zasićenje eritrocitne CA-II brinzolamidom postignuto je unutar 4 tjedna (eritrocitna koncentracija od oko 20 M).
• Gently press on the base of the bottle to release one drop of AZOPT at a time. 
• Laganim pritiskom kažiprsta na dno okrenute bočice istisnite po jednu kapljicu AZOPTA
- If you have any further questions, ask your doctor or your pharmacist. 
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
Oral carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/or physical coordination (see also section 4.4 and section 4.8). 
Oralni inhibitori karboanhidraze mogu utjecati na sposobnost obavljanja radnji koje zahtijevaju pribranost i/ili tjelesnu kooridinaciju (vidjeti također dio 4.4 i dio 4.8).
There is limited experience with AZOPT in the treatment of patients with pseudoexfoliative glaucoma or pigmentary glaucoma. 
Iskustva primjene AZOPTA u liječenju bolesnika s pseudoeksfolijativnim glaukomom ili pigmentnim glaukomom su ograničena.
Uncommon: nasopharyngitis, pharyngitis, sinusitis Not Known: rhinitis 
Manje često: nazofaringitis, faringitis, sinusitis Nepoznato: rinitis
How to use AZOPT 
Kako primjenjivati AZOPT
Similar studies in rats resulted in slightly reduced ossification of skull and sternebrae of foetuses of dams receiving brinzolamide at doses of 18 mg/kg/day (375 times the recommended human ophthalmic dose), but not 6 mg/kg/day. 
Slična ispitivanja na štakorima pokazala su blago smanjenje okoštavanja lubanje i sternebra kod fetusa ženki koje su primale brinzolamid u dozama od 18 mg/kg/dan (375 puta više od preporučene doze u oko za ljude), ali ne pri 6 mg/kg/dan.
There are no or limited amount of data from the use of ophthalmic brinzolamide in pregnant women. 
Nema podataka ili su podaci o primjeni oftalmološkog brinzolamida u trudnica ograničeni.
Eye drops, suspension. 
Kapi za oko, suspenzija.
In a topical ocular study, at steady-state, brinzolamide RBC concentrations were similar to those found in the oral study, but levels of N-desethylbrinzolamide were lower. 
U ispitivanju lokalne primjene u oko, u stanju dinamičke ravnoteže, koncentracija brinzolamida u eritrocitima bila je slična vrijednosti dobivenoj u oralnoj studiji, ali je koncentracija N-desetilbrinzolamida bila niža.
The same types of adverse reactions that are attributable to sulphonamides may occur with topical administration. 
Isti tip nuspojava koje se povezuju sa sulfonamidima može se pojaviti kod lokalne primjene.
It is unknown whether brinzolamide/metabolites are excreted in human milk following topical ocular administration. 
Nije poznato izlučuje li se brinzolamid/metaboliti u majčino mlijeko nakon lokalne primjene u oko.
AZOPT contains a preservative (benzalkonium chloride) which may be absorbed by soft contact lenses and may change the colour of the contact lenses. 
AZOPT sadrži konzervans (benzalkonijev klorid) kojeg mogu apsorbirati meke kontaktne leće zbog čega se može promijeniti njihova boja.
This pressure can lead to an illness called glaucoma. 
Povišeni tlak u oku može dovesti do bolesti koja se naziva glaukom.
Each ml of suspension contains 0.1 mg benzalkonium chloride. 
Svaki ml suspenzije sadrži 0,1 mg benzalkonijeva klorida.
Oral carbonic anhydrase inhibitors may impair the ability to perform tasks requiring mental alertness and/or physical coordination. 
Oralni inhibitori karboanhidraze mogu umanjiti sposobnost obavljajnja zadaća koje zahtijevaju pribranost i/ili tjelesnu koordinaciju.
CARTON FOR SINGLE BOTTLE, 5 ml, 10 ml + CARTON FOR 3 x 5 ml BOTTLES 
KUTIJA ZA JEDNU BOČICU, 5 ml, 10 ml + KUTIJA ZA 3 BOČICE x 5 ml
Uncommon: apathy, depression, depressed mood, libido decreased, nightmare, nervousness Rare: insomnia 
Manje često: apatija, depresija, potištenost, smanjen libido, noćne more, nervoza
Only use AZOPT in both eyes if your doctor told you to. Take it for as long as your doctor told you to. 
Lijek primijenite u oba oka samo ako Vam je to savjetovao liječnik.
5 and 10 ml opaque low density polyethylene bottles with polypropylene screw caps (droptainer). 
Neprozirne bočice volumena 5 i 10 ml od polietilena niske gustoće s polipropilenskom navojnim zatvaračem (droptainer).
AZOPT is absorbed systemically and therefore this may occur with topical administration. 
AZOPT se apsorbira sistemski te su stoga ti učinci mogući i pri lokalnoj primjeni.
If you are taking another carbonic anhydrase inhibitor (acetazolamide or dorzolamide, see section 1 What AZOPT is and what it is used for), talk to your doctor. 
Ako istodobno uzimate neki drugi inhibitor karboanhidraze (acetazolamid ili dorzolamid, vidjeti dio 1.
AZOPT has not been studied in patients with narrowangle glaucoma and its use is not recommended in these patients. 
AZOPT nije ispitivan kod bolesnika s glaukomom uskog kuta, te se njihova primjena ne preporučuje kod ovih bolesnika.
AZOPT is a sulphonamide inhibitor of carbonic anhydrase with systemic absorption. 
AZOPT je sulfonamidni inhibitor karboanhidraze sa sistemskom apsorpcijom.
N-desethylbrinzolamide RBC concentrations increased and total RBC CA activity decreased with decreasing creatinine clearance but brinzolamide RBC concentrations and CA-II activity remained unchanged. 
Sa smanjenjem klirensa kreatinina povećavala se je koncentracija N-desetil-brinzolamida u eritrocitima te smanjila ukupna aktivnost CA u eritrocitima, ali su koncentracija brinzolamida u eritrocitima i aktivnost CA-II ostale nepromijenjene.
During lactation, the no adverse effect level in the offspring was 5 mg/kg/day. 
Doza pri kojoj nije bilo nuspojava kod podmlatka tijekom dojenja iznosila je 5 mg/kg/dan.
AZOPT has not been studied in patients with hepatic impairment and is therefore not recommended in such patients. 
AZOPT nije ispitivan u bolesnika s oštećenjem jetre te se stoga primjena kod tih bolesnika ne preporučuje.
How to store AZOPT 
Kako čuvati AZOPT
Contains benzalkonium chloride, mannitol (E421), carbomer 974P, tyloxapol, edetate disodium, sodium chloride, hydrochloric acid/sodium hydroxide (to adjust pH) and purified water. 
Sadrži benzalkonijev klorid, manitol (E421), karbomer 974P, tiloksapol, dinatrijev edetat, natrijev klorid, kloridnu kiselinu/natrijev hidroksid (za podešavanje pH) i pročišćenu vodu.
- The other ingredients are benzalkonium chloride, carbomer 974P, edetate disodium, mannitol (E421), purified water, sodium chloride, tyloxapol. 
- Drugi sastojci su: benzalkonijev klorid, karbomer 974P, dinatrijev edetat, manitol (E421), pročišćena voda, natrijev klorid, tiloksapol.
D CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT 
UVJETI ILI OGRANIČENJA VEZANA UZ SIGURNU I UČINKOVITU PRIMJENU LIJEKA
Uncommon: red blood cell count decreased, blood chloride increased 
Poremećaji krvi i limfnog sustava Manje često: smanjenje broja crvenih krvnih stanica, povećanje klorida u krvi
Uncommon: motor dysfunction, amnesia, dizziness, paraesthesia, headache 
Manje često: poremećaj motorike, amnezija, omaglica, parestezije, glavobolja
No unexpected adverse reactions have been observed with AZOPT when used as adjunctive therapy to travoprost. 
Neočekivane nuspojave nisu zabilježene kod primjene AZOPTA kao dodatne terapije s travoprostom.
Acid-base disturbances have been reported with oral carbonic anhydrase inhibitors. 
Acidobazični poremećaji zabilježeni su s oralnim inhibitorima karboanhidraze.
Some patients were naive to IOP therapy whilst others were on other IOP-lowering medicinal product(s). 
Nekim bolesnicima to je bila prva terapija IOT-a, dok su drugi već bili na terapiji nekim od lijekova za sniženje IOT-a.
- if you have too much acidity in your blood (a condition called hyperchloraemic acidosis). 
AZOPT može uzrokovati istu alergiju. ako imate previsoku kiselost krvi (stanje nazvano hiperkloremična acidoza).
The potential for interactions must be considered in patients receiving AZOPT. 
U bolesnika koji uzimaju AZOPT mora se uzeti u obzir mogućnost interakcija.
- if you are allergic to brinzolamide or any of the other ingredients of this medicine (listed in section 6). 
ako ste alergični na brinzolamid ili neki drugi sastojak ovog lijeka (naveden u dijelu 6.). ako ste alergični na lijekove koje nazivamo sulfonamidi.
Studies have not been performed to evaluate the effect of topical ocular administration of brinzolamide on human fertility. 
Nisu provedena ispitivanja procjene utjecaja brinzolamida primijenjenog lokalno u oko na plodnost u ljudi.